ClinicalTrials.gg
CompletedNCT03324139TRACIPUpdated Apr 22, 2024

Treatment of Intrauterine Growth Restriction With Low Molecular Heparin.

A Phase 3 interventional study of Low molecular weight heparin and Placebos in Intrauterine Growth Restriction, sponsored by Fundació Sant Joan de Déu. Completed at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by Fundació Sant Joan de Déu · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 18 studies in Fetal Growth Retardation with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Fetal Growth Retardation · Spain.

Enrollment
11th of 11
48 · median 340
Started
2018
with 2 others
Phase 3
2 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
1 of 18
Fundació Sant Joan de Déu

Among the 18 studies in Fetal Growth Retardation with a site in Spain, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 3, and was the 7th registered.

Fetal Growth Retardation

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

Browse Fetal Growth Retardation studies →

Open to participants now

7 of the 18 studies in Fetal Growth Retardation with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Fetal Growth Retardation with a site in Spain, or all of them as a file.
02

Study summary

TREATMENT OF INTRAUTERINE GROWTH RESTRICTION WITH LOW MOLECULAR WEIGHT HEPARIN.

Read the detailed description

TREATMENT OF INTRAUTERINE GROWTH RESTRICTION WITH LOW MOLECULAR WEIGHT HEPARIN: RANDOMIZED CLINICAL TRIAL (TRACIP STUDY).

03

Conditions studied

  • Intrauterine Growth Restriction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women older than 18 years.
  • Unique gestations
  • Diagnosis of early placental intrauterine growth (according to Delphi classification): \<32 weeks at diagnosis + Doppler AU with absent / reverse flow or (estimated fetal weight \<10 percentile + pulsed Doppler ultrasonography) or (estimated fetal weight \<percentile 10 + pulsed uterine artery Doppler).
  • Patient giving written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Chromosopathies, genetic alterations or fetal malformations.
  • Diagnostic treatment with low molecular weight heparins, oral anticoagulants or acetylsalicylic acid prior to inclusion.
  • History of heparin-induced thrombocytopenia.
  • Active hemorrhage or increased risk of bleeding due to changes in hemostasis.
  • Severe hepatic or pancreatic function disorder.
  • Organic lesions that may bleed (eg, active peptic ulcer, hemorrhagic stroke, aneurysms, or brain tumors).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Study Group

    Treatment with low molecular weight Heparin.

    Drug: Low molecular weight heparin

  • Placebo comparator
    Control Group

    Treatment with Placebo.

    Drug: Placebos

Interventions

  • DrugHeparin, Low-Molecular-WeightStudies of Heparin, Low-Molecular-WeightHeparin, Low-Molecular-Weight pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).

    Also known as: heparin

  • DrugPlacebos

    Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).

    Also known as: sodium chloride (0.9%)

06

What researchers measure

Primary outcomes

  1. Efficacy of low molecular weight heparin in the prolongation of gestation.

    Measured as gestational age (weeks) at birth (dated by ultrasonography \<14 weeks by measurement of caudal skull length).

    Time frame: 13 weeks maximum

Secondary outcomes

  1. Efficacy of low molecular weight heparin in reducing neonatal morbidity

    Measured as the presence of one or more of the following: Perinatal mortality (\> 22 weeks of gestation - \<28 days postpartum), Significant neonatal morbidity (convulsions, intraventricular haemorrhage\> grade III, periventricular leukomalacia, hypoxic-ischemic encephalopathy, abnormal electroencephalogram, necrotizing enterocolitis, acute renal failure (serum creatinine\> 1.5 mg / dL) or cardiac failure (requiring inotropic agents), Perinatal mortality (22 weeks to 28 postnatal days), Biomarkers.

    Time frame: 13 weeks maximum

  2. Demonstrate that low molecular weight heparin improves the pro-angiogenic and anti-inflammatory profile.

    Measured as the presence of one or more of the following: mother blood biomarkers (sFlt and PlGF), biomerkers, umbilical cord blood biomarkers (TNF alfa, IL6, IFN gamma, FGF basic, VEGF and PlGF), mRNA in trophoblast.( IL6, INFg, TNF alfa, VEGFA, VEGFB, FGF2 y RQVEGF).

    Time frame: 13 weeks maximum

  3. Efficacy of low molecular weight heparin in reducing thrombotic and ischemic placental lesions

    Measured as the presence of one or more of the following: Intrauterine growth retardation (Neonatal weight below the 10th percentile of our population + umbilical artery pulsatility index during the third trimester (on two separate occasions\> 48h) above the 95th percentile), Preeclampsia, Gestational age (weeks) at birth, Premature delivery before 34 weeks of gestation, Urgent cesarean section due to loss of fetal well-being, Neonatal weight, Neonatal acidosis (arterial pH \<7.10 + EB\> 12mEq / L), Days stay in the Neonatal Intensive Care Unit, mRNA in trophoblast.

    Time frame: 13 weeks maximum

07

Study locations

1 site
  • Hospital Sant Joan de Déu
    Esplugues de Llobregat, Barcelona 08950, Spain
08

References and documents

Publications

  • Mazarico E, Peguero A, Camprubi M, Rovira C, Gomez Roig MD, Oros D, Ibanez-Burillo P, Schoorlemmer J, Masoller N, Tassies MD, Figueras F. Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP). BMJ Open. 2018 Oct 23;8(10):e020501. doi: 10.1136/bmjopen-2017-020501. PubMed 30355790 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Apr 2022, 51 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2017
First posted
Oct 27, 2017
StartActual
Jan 25, 2018
Primary completionActual
Apr 30, 2022
CompletionActual
Feb 19, 2023
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03324139
Lead sponsor
Fundació Sant Joan de Déu
Collaborators
Servicio de Asesoría a la Investigación y Logística SL
Responsible party
Sponsor
First posted
Oct 27, 2017
Start date
Jan 25, 2018
Primary completion
Apr 30, 2022
Completion
Feb 19, 2023
Last update
Apr 22, 2024

Study contacts

Edurne Mazarico
principal investigator · Hospital Sant Joan de Deu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heparin, Low-Molecular-Weight

Start the discussion